Final 3-year results of the Dasatinib Discontinuation Trial in Patients with Chronic Myeloid Leukemia who received dasatinib as a second line treatment
Conclusion These findings suggest that discontinuation of second- or subsequent-line dasatinib after a sustained DMR of at least 1 year is feasible, particularly for patients with no prior history of imatinib resistance. In addition, the NK cell count was associated with TFR. (DADI trial; UMIN000005130).
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Japan Health | Leukemia | Lymphoma | Myeloma | Nilotinib | Tasigna